Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Cash from Operations came in at 2514000000.0 in Q1 2026, down 39.77% year-on-year from 4174000000.0 in Q1 2025, and down 65.6% quarter-over-quarter from 7309000000.0 in Q4 2025.
Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Cash from Operations across 18 years of filings, most recently posting 2514000000.0 for Q1 2026.
- Cash from Operations for Q1 2026 came in at 2514000000.0, down 39.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 22870000000.0 (down 7.72% YoY), and the FY2025 annual result was 24530000000.0, up 1.09% from the prior year.
- Cash from Operations came in at 2514000000.0 for Q1 2026 at Johnson & Johnson, down from 7309000000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9169000000.0 in Q3 2025 to a low of 2514000000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 4182000000.0 (2023), against an average of 5439733333.33.
- Across the five-year window, Cash from Operations jumped 123.63% in 2023 and slumped 39.77% in 2026, its largest moves.
- Johnson & Johnson's Cash from Operations stood at 3979000000.0 in 2022, then soared by 97.61% to 7863000000.0 in 2023, then decreased by 11.19% to 6983000000.0 in 2024, then grew by 4.67% to 7309000000.0 in 2025, then tumbled by 65.6% to 2514000000.0 in 2026.
- The last three Cash from Operations figures came in at 2514000000.0 (Q1 2026), 7309000000.0 (Q4 2025), and 9169000000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 1.82 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 2.51 Bn |
| Mar 29, 2026 | 2.51 Bn |
| Dec 28, 2025 | 7.31 Bn |
| Dec 28, 2025 | 7.31 Bn |
| Sep 28, 2025 | 9.17 Bn |
| Sep 28, 2025 | 9.17 Bn |
| Jun 29, 2025 | 3.88 Bn |
| Jun 29, 2025 | 3.88 Bn |
| Mar 30, 2025 | 4.17 Bn |
| Mar 30, 2025 | 4.17 Bn |
| Dec 29, 2024 | 6.98 Bn |
| Dec 29, 2024 | 6.98 Bn |
| Sep 29, 2024 | 7.99 Bn |
| Sep 29, 2024 | 7.99 Bn |
| Jun 30, 2024 | 5.63 Bn |
| Jun 30, 2024 | 5.63 Bn |
| Mar 31, 2024 | 3.66 Bn |
| Mar 31, 2024 | 3.66 Bn |
| Dec 31, 2023 | 7.86 Bn |
| Dec 31, 2023 | 7.86 Bn |